Conditions: Type 2 Diabetes
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 599
Healthy volunteers: no

Brief summary:
The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.

Detailed description:

Arms:
arm 1: LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks

Metformin: at least 1500 mg/day, oral, for 26 weeks arm 2: Liraglutide 0.6 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.2 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.8 mg, SC, once daily for 24 weeks

Metformin: at least 1500 mg/day, oral, for 26 weeks

Interventions: intervention 1: LY2189265 intervention 2: Liraglutide intervention 3: Metformin
Intervention descriptions: intervention 1: Administered SC intervention 2: Administered SC intervention 3: None

Protocol document: